Instalab
logoInstalab

Candida Species

Stool Test
See whether yeast is overgrowing in your gut, an early signal of microbiome imbalance that routine stool tests skip.

Should you take a Candida Species test?

This test is most useful if any of these apply to you.

Recovering From Recent Antibiotics
If you've had one or more antibiotic courses recently, this test can show whether yeast has bloomed in the disrupted gut ecosystem they left behind.
Dealing With Recurrent Yeast Infections
If vaginal or oral yeast infections keep coming back, gut overgrowth may be the reservoir; this test helps you see whether that's the case.
Living With Persistent Gut Symptoms
Bloating, irregular bowels, or brain fog with no clear cause sometimes track with microbiome imbalance; this test adds yeast to that picture.
Optimizing Your Microbiome
If you're already working on gut health, this test gives you a yeast-specific data point alongside bacterial diversity to track over time.

About Candida Species

Candida albicans lives quietly in most healthy people. It sits on your skin, in your mouth, throughout your gut, and on other mucosal surfaces, usually in modest amounts that cause no trouble. When something tips the balance, an antibiotic course, a stretch of poor sleep and stress, a weakened immune response, this yeast can multiply and start to behave very differently.

A stool-based check for Candida albicans gives you a window into whether yeast is overgrowing in your gut, a pattern linked to digestive symptoms, recurrent mucosal infections, and broader microbiome disruption. This is an exploratory marker rather than a definitive diagnostic, and the result is most useful when interpreted alongside symptoms and the rest of your microbiome picture.

What This Yeast Actually Is

Candida albicans is a single-celled fungus that can switch between a round yeast form and a longer thread-like form (called hyphae). That shape-shifting matters: the thread-like form is what allows it to push into tissue and form sticky communities on surfaces (called biofilms) that resist both your immune system and antifungal drugs.

Its outer wall is built from layers of sugar polymers (chitin and beta-glucans) wrapped in proteins that act like grappling hooks for attaching to your cells. It also releases damaging enzymes, including secreted aspartyl proteinases, phospholipases, and a small pore-punching peptide called candidalysin, that can injure the cells lining your gut, mouth, or vagina.

Why Gut Levels Matter

Candida intestinal carriage is the rule, not the exception. In a study of nearly 700 healthy adults, the majority carried Candida albicans in the gut without overt disease. The reason that does not translate into universal infection is that healthy bacteria, intact gut lining, and a working immune system normally keep the yeast in check.

When that balance breaks, gut Candida overgrowth becomes a starting point for problems. The gut is recognized as a major source of bloodstream Candida infections, with yeast translocating across a damaged intestinal barrier into the circulation. Elevated intestinal Candida has also been observed in inflammatory bowel disease, irritable bowel syndrome, neonatal necrotizing enterocolitis, colorectal cancer, and primary sclerosing cholangitis, and Candida-related antibodies appear in both Crohn's disease and coeliac disease.

Invasive Candidiasis Risk

Candida albicans is the leading cause of invasive candidiasis worldwide and is listed by the World Health Organization as a critical-priority fungal pathogen. In hospitalized patients with bloodstream Candida infections, mortality is high: a multinational ICU study found mortality above 50% for C. albicans candidaemia, with rates trending even higher for non-albicans species. Most invasive cases trace back to gut colonization that crossed the intestinal barrier under conditions of immune suppression, critical illness, broad antibiotic use, or indwelling devices.

For someone who is otherwise healthy, this severe end of the spectrum is unlikely. But the underlying biology is the same: a yeast that lives quietly in the gut becomes a problem when it expands, sticks to tissue, and forms biofilms. A high stool reading is not a diagnosis of invasive disease, but it does flag that the conditions favoring overgrowth may be in place.

Mucosal Infections and Recurrent Problems

The same organism is responsible for several familiar conditions: oral thrush (white coating on the tongue or cheeks), vulvovaginal candidiasis (yeast infections), and skin yeast infections in moist areas. In a study of 100 women with recurrent vulvovaginal candidiasis, the Candida albicans strains isolated showed stronger biofilm formation, higher expression of virulence genes, and increased antifungal resistance compared with strains from women who were merely colonized.

Oral Candida overgrowth has its own consequences. A meta-analysis found that children with oral Candida albicans had substantially higher odds of early childhood cavities compared with children without. In a separate study of 100 patients with oral thrush, C. albicans dominated the oral fungal community and fungal diversity collapsed, a pattern consistent with overgrowth-driven disease.

What High and Low Levels Mean

Because Candida albicans is an organism rather than a hormone or protein your body makes, "high" and "low" mean colonization burden rather than a level of one of your own molecules. A low or undetectable reading is generally considered benign: many healthy people have very little detectable yeast and that is not described as a deficiency in any of the available research.

A high reading reflects increased Candida load and, often, disrupted microbial balance around it. It does not by itself prove that yeast is causing your symptoms, because a substantial fraction of healthy people also carry detectable Candida. The clinical concern rises when high yeast levels appear together with symptoms, with markers of inflammation, with reduced bacterial diversity, or in people with risk factors like recent antibiotics, immune suppression, or a diet pattern that favors yeast.

Reading This Marker Honestly

Stool Candida testing sits in the research-and-exploratory zone of lab medicine. There are no consensus reference ranges that say "this number means disease." Different labs use different methods (culture, PCR, sequencing) and report results in different units, so direct comparison between labs can be misleading. Detection thresholds vary, and a single reading captures one moment in a system that shifts day to day with diet, sleep, antibiotics, and stress.

What that means in practice: do not treat a Candida result like a cholesterol number. Treat it like one data point in a microbiome picture. A high reading earns attention; it does not by itself prescribe a course of action.

Tracking Your Trend

Serial measurement is more useful than a single result. Gut microbiota composition can shift meaningfully over weeks in response to antibiotics, diet, illness, and stress, and Candida abundance moves with that broader ecosystem. A single high reading might reflect a transient bloom after an antibiotic course; a persistently high reading across two or three tests months apart suggests a more durable imbalance worth investigating.

A reasonable cadence: a baseline test when you are curious or symptomatic, a retest in 3 to 6 months if you are making changes to address the result or recovering from an antibiotic course or illness, then annually as part of broader microbiome monitoring. If you are tracking response to a specific intervention, time the retest to when you would expect the gut community to have stabilized after the change, typically at least 8 to 12 weeks.

When Results Can Be Misleading

  • Recent antibiotic use: broad-spectrum antibiotics suppress competing gut bacteria and can produce a temporary spike in Candida that is not your true baseline; if possible, test at least 4 to 6 weeks after finishing a course.
  • Recent antifungal use: antifungal medications can transiently suppress detectable yeast, producing a falsely reassuring result that does not reflect your usual gut state.
  • Diet in the days before collection: a recent stretch of very high sugar or alcohol intake can shift yeast detection upward temporarily; an unusually restrictive recent diet can shift it downward.
  • Sample handling: stool samples that sit too long at room temperature before processing can show distorted microbial readings; follow the collection kit's storage and shipping instructions exactly.

What to Do With an Unexpected Result

A high stool Candida reading should prompt a closer look rather than an immediate antifungal prescription. Pair it with the rest of the picture: are you having digestive symptoms, recurrent yeast infections, oral thrush, or skin yeast issues? Are inflammation markers like stool calprotectin or secretory IgA out of pattern? Is bacterial diversity reduced? Do you have a history of repeated antibiotic courses, immune suppression, or uncontrolled blood sugar?

Combinations matter more than the Candida number alone. High Candida plus high calprotectin plus symptoms is a different picture than high Candida in someone who feels fine. If results and symptoms align, a gastroenterologist or integrative practitioner familiar with microbiome testing can help decide whether to confirm with a different method, pursue antifungal treatment, or focus first on restoring bacterial balance and addressing upstream drivers. For systemic symptoms or recurrent mucosal infections, an infectious disease consultation may be appropriate.

What Moves This Biomarker

Evidence-backed interventions that affect your Candida Species level

Increase
Take a course of broad-spectrum antibiotics
Broad-spectrum antibiotics wipe out the competing bacteria that normally keep Candida in check, allowing yeast to expand in the gut and on mucosal surfaces. This is one of the most consistent triggers of Candida overgrowth and a major risk factor for invasive candidiasis in hospitalized patients, where antibiotic exposure is independently linked to higher invasive Candida risk.
MedicationStrong Evidence
Decrease
Take prescription antifungal medications (fluconazole, echinocandins, amphotericin B)
Antifungal drugs directly suppress Candida growth and are the standard-of-care treatment for confirmed Candida infections. A WHO systematic review found that C. albicans remains broadly susceptible to echinocandins, amphotericin B, and flucytosine, with fluconazole resistance still relatively uncommon but rising in some regions. These are prescription medications used for diagnosed infections, not for incidentally elevated stool readings without symptoms.
MedicationStrong Evidence
Increase
Take systemic corticosteroids or other immunosuppressive therapy
Systemic immune suppression from corticosteroids, chemotherapy, or other immunosuppressants is a recognized risk factor for Candida overgrowth and infection because it weakens the immune control that normally keeps yeast populations small. This is a genuine driver of Candida disease in vulnerable patients, not just a lab artifact.
MedicationModerate Evidence
Increase
Have uncontrolled diabetes or high blood sugar
Elevated blood sugar provides fuel for Candida growth and impairs the immune response that normally keeps it in check. Diabetes is a consistently reported risk factor across studies of Candida skin infection, oral candidiasis, vulvovaginal candidiasis, and invasive disease. Better glycemic control reduces this risk by removing both the substrate and the immune handicap.
LifestyleModerate Evidence
Decrease
Take probiotics for oral candidiasis
A systematic review of probiotic trials in oral candidiasis found a beneficial effect on Candida burden and clinical outcomes, with effect size varying by population and study quality. The most direct evidence is for oral Candida; whether the same probiotic strategies reliably lower gut Candida burden has not been as clearly established in human trials.
SupplementModest Evidence

Frequently Asked Questions

References

16 studies
  1. Parambath S, Dao a, Kim HY, Zawahir S, Alastruey-izquierdo a, Tacconelli E, Govender N, Oladele R, Colombo a, Sorrell TC, Ramon-pardo P, Fusire T, Gigante V, Sati H, Morrissey CO, Alffenaar JW, Beardsley JMedical Mycology2024
  2. Katsipoulaki M, Stappers MHT, Malavia-jones D, Brunke S, Hube B, Gow NAMicrobiology and Molecular Biology Reviews2024
  3. Kreulen IAM, De Jonge WD, Van Den Wijngaard RM, Van Thiel IAMMycopathologia2023
  4. Basmaciyan L, Bon F, Paradis T, Lapaquette P, Dalle FTissue Barriers2019
  5. Delavy M, Sertour N, Patin E, Le Chatelier E, Cole N, Dubois F, Xie Z, Saint-andré V, Manichanh C, Walker AW, Quintana-murci L, Duffy D, D'enfert C, Bougnoux MGut Microbes2023